Want to see MREO full AI Analyst Report?

Mereo Biopharma Group Plc (MREO) Price & Analysis

893 Followers

MREO Stock Chart & Stats

$0.29

>-$0.01(-1.10%)

At close: Jul 24 4:00 PM EDT

$0.29

>-$0.01(-1.10%)

Day’s Range― - ―

52-Week Range$0.20 - $2.37

Previous CloseN/A

Volume389.50K

Average Volume (3M)1.26M

Market Cap

$49.96M

Enterprise Value$21.97

Total Cash (Recent Filing)$30.12M

Total Debt (Recent Filing)$1.03M

Price to Earnings (P/E)―

Beta1.10

Next Earnings

Nov 17, 2026

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding159,690,980

10 Day Avg. Volume647,111

30 Day Avg. Volume1,259,275

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)1.62

Price to Sales (P/S)132.86

P/FCF Ratio-2.14

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$3.00

Price Target Upside934.48% Upside

Rating ConsensusHold

Number of Analyst Covering3

EPS Forecast (FY)-0.06

Revenue Forecast (FY)$2.37M

Bulls Say, Bears Say

Bulls Say

Capital-light Alvelestat PartnershipThe Sentynl agreement could shift Phase 3 funding and future commercialization support to a larger partner while preserving royalties and non-U.S. rights, reducing Mereo’s need to finance the program alone.

Extended Cash RunwayRunway into late 2027 gives management time to advance alvelestat and setrusumab without immediate dependence on capital markets. Potential partner payments could further extend funding capacity if the option is exercised.

Low Balance-sheet LeverageMinimal reported debt limits interest and refinancing pressure relative to highly levered biotech peers. This provides some financial flexibility while the company pursues clinical milestones and partnership-based funding.

Bears Say

Near-zero Revenue And Persistent LossesThe lack of current revenue leaves Mereo dependent on clinical progress, partnerships, and financing rather than an operating commercial base. Persistent losses reduce internal funding capacity and increase execution risk.

Sustained Cash BurnOngoing negative operating and free cash flow means the company cannot currently self-fund development. Continued trials and regulatory work will require disciplined spending, partner funding, or future external capital.

Nasdaq Listing Compliance RiskThe extension preserves market access temporarily but leaves a defined compliance deadline and potential delisting risk. Loss of the Nasdaq listing could impair financing access, liquidity, and visibility with institutional investors.

Mereo Biopharma Group Plc News

JPMorgan downgrades Mereo to Underweight on regulatory uncertainty

JPMorgan analyst Priyanka Grover last night downgraded Mereo BioPharma (MREO) to Underweight from Neutral without a price target...

2d ago

MREO

Mereo BioPharma downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Mereo BioPharma (MREO) to Underweight from Neutral without a price target Published first on TheFly –...

2d ago

MREO

Mereo BioPharma reports Q2 EPS (1c), consensus (1c)

“The partnership with Sentynl Therapeutics which we announced earlier today marks a significant milestone for our alvelestat program...

10d ago

MREO

Mereo BioPharma licenses alvelestat to Sentynl Therapeutics in the U.S.

Mereo BioPharma (MREO) and Sentynl Therapeutics, a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences, have entered...

10d ago

MREO

Mereo BioPharma Granted Nasdaq Extension to Regain Compliance

An announcement from Mereo Biopharma Group Plc ( ($MREO) ) is now available. Mereo BioPharma Group plc is...

2d ago

MREO

Mereo Biopharma Grants Sentynl Rights to Alvelestat Therapy

The latest announcement is out from Mereo Biopharma Group Plc ( ($MREO) ). On August 11, 2026, Mereo...

10d ago

MREO

MREO Upcoming Earnings Report: What to Expect?

Mereo Biopharma (MREO) is scheduled to report 1st quarter earnings on 05/20/2026, before the market opens. Regarding Q1...

3M ago

MREO

Mereo BioPharma Shareholders Approve All AGM Resolutions

Mereo Biopharma Group Plc ( ($MREO) ) has shared an update. On May 14, 2026, Mereo BioPharma Group...

3M ago

MREO

Mereo BioPharma reports Q1 EPS (1c), consensus 0c

“Based on extensive analysis of data across the two global Phase 3 studies of setrusumab in osteogenesis imperfecta...

3M ago

MREO

Mereo Biopharma Announces Upcoming Board Change, Ensuring Continuity

Mereo Biopharma Group Plc ( ($MREO) ) has shared an announcement. On March 26, 2026, Mereo BioPharma Group...

5M ago

MREO

Shareholders Sue Mereo BioPharma (MREO) Over Brittle Bone Drug Claims

A class action was filed against Mereo BioPharma Group ($MREO) on February 4, 2026. Plaintiffs – Mereo shareholders...

5M ago

NVS

MREO

Mereo BioPharma downgraded to Neutral from Overweight at JPMorgan

JPMorgan on Friday night downgraded Mereo BioPharma (MREO) to Neutral from Overweight without a price target The firm...

5M ago

MREO

Mereo BioPharma downgraded to Neutral from Overweight at JPMorgan

JPMorgan downgraded Mereo BioPharma (MREO) to Neutral from Overweight. Published first on TheFly – the ultimate source for...

5M ago

MREO

Balanced Risk-Reward Amid Clinical Uncertainty: Maintaining Hold on Mereo BioPharma

LifeSci Capital analyst Kate Dellorusso has maintained their neutral stance on MREO stock, giving a Hold rating today....

5M ago

MREO

MREO FAQ

What was Mereo Biopharma Group Plc’s price range in the past 12 months?

Mereo Biopharma Group Plc lowest stock price was $0.20 and its highest was $2.37 in the past 12 months.

What is Mereo Biopharma Group Plc’s market cap?

Mereo Biopharma Group Plc’s market cap is $49.96M.

When is Mereo Biopharma Group Plc’s upcoming earnings report date?

Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 17, 2026 which is in 88 days.

How were Mereo Biopharma Group Plc’s earnings last quarter?

Mereo Biopharma Group Plc released its earnings results on Aug 11, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.002.

Is Mereo Biopharma Group Plc overvalued?

According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mereo Biopharma Group Plc pay dividends?

Mereo Biopharma Group Plc does not currently pay dividends.

What is Mereo Biopharma Group Plc’s EPS estimate?

Mereo Biopharma Group Plc’s EPS estimate is -0.02.

How many shares outstanding does Mereo Biopharma Group Plc have?

Mereo Biopharma Group Plc has 159,690,980 shares outstanding.

What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?

Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went up 12.132%.

Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?

Currently, no hedge funds are holding shares in MREO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Mereo Biopharma Group Plc Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-44.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mereo Biopharma Group Plc

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.

Mereo Biopharma Group Plc (MREO) Earnings & Revenues

Historic Earnings Reports

MREO Stock 12 Month Forecast

Average Price Target

$3.00

▲(934.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.342,0.5464615384615384,0.7509230769230769,0.9553846153846153,1.1598461538461537,1.3643076923076922,1.5687692307692307,1.7732307692307692,1.9776923076923076,2.182153846153846,2.3866153846153844,2.591076923076923,2.7955384615384613,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.342,0.5464615384615384,0.7509230769230769,0.9553846153846153,1.1598461538461537,1.3643076923076922,1.5687692307692307,1.7732307692307692,1.9776923076923076,2.182153846153846,2.3866153846153844,2.591076923076923,2.7955384615384613,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.342,0.5464615384615384,0.7509230769230769,0.9553846153846153,1.1598461538461537,1.3643076923076922,1.5687692307692307,1.7732307692307692,1.9776923076923076,2.182153846153846,2.3866153846153844,2.591076923076923,2.7955384615384613,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.416,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.432,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.397,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.307,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.323,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.342,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >